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The concept of liver transplantation is a relatively recent one. The first 
descriptions of liver replacement in experimental animals were published 
less than 25 years ago [I, 2] and the first attempt at clinical liver transplanta-
tion was not made until March I, 1963 [3]. However, the great avalanche of 
human liver transplantations worldwide did not begin until 1980, just about 
5 years ago. A number of factors contributed to the growing interest in and 
success with orthotopic liver transplantation, but, of these, the most impor-
tant by far was the introduction of the new immunosuppressive agent, ciclo-
sporin. In the following sections, the influence of this drug as well as other 
factors which conspired to make liver transplantation practical will be 
described. The principal topics to be considered will be immunosuppression, 
tissue matching, improvements in surgical techniques, and advances in organ 
procurement and preservation. 
Immunosuppression 
The possibility of obtaining truly long survival after liver transplantation 
between outbred mongrel dogs was demonstrated more than 20 years ago [4]. 
From a series of more than 100 canine experiments, 10 dogs under treatment 
1 Supported by Research Grants from the Veterans Administration and Project Grant 
No.AM-29961 from the National Institutes of Health, Bethesda, Md. 
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with azathioprine lived for 4 postoperative months, after which their drug 
therapy was discontinued. A number of these animals lived on for long 
periods [5], and one did not die until more than 10 years later. Within 2 years, 
similar results were obtained with heterologous antilymphocyte serum (ALS) 
and its globulin derivative (ALG) [6]. 
Proof of the feasibility of liver replacement under these difficult labora-
tory conditions was the great stimulus for the first clinical trials and for persis-
tance in these trials in spite of repeated early failures. The first extended sur-
vival of a human liver recipient was accomplished in the summer of 1967 [7], 
and the longest survival of any patient in the world today is now more than 
15 years. This recipient whose original disease was biliary atresia with an 
incidental hepatoma was treated with azathioprine, prednisone, and ALG. 
Clinical Immunosuppressive Regimens before Ciclosporin 
With Renal Transplantation 
The various drug regimens· that have made whole liver transplantation 
feasible were worked out with the simpler model of renal transplantation 
(table I). The first step was the use of azathioprine as the sole or principal 
immunosuppressive agent in the Boston trials of 1962 [8]. There were no long 
survivors and since that time, it has been recognized that cadaver organ 
transplantation could rarely, if ever, be successful using azathioprine alone. 
The so-called modem era of whole organ transplantation began in 1962 
and 1963 when it was realized that azathioprine and steroids had at least 
additive, if not synergistic, actions [9]. With the introduction of this so-called 
double-drug therapy which was quickly adopted in at least three other cen-
ters [lO-12], significant numbers of patients began to emerge from renal 
transplantation clinics with chronically functioning grafts [13]. However, 
satisfactory results then and for more than a decade were obtained only with 
living related donors. The morbidity and mortality from the transplantation 
of cadaveric kidneys were excessive and the rate of graft function at one year 
hovered at the 50% range for many years [14]. 
The addition of antilymphocyte globulin (ALG) as a third and short-
term immunosuppressive adjunct [6, 15] improved the results in most centers 
in which this expedient was tried. However, the usefulness of ALG was 
limited by the facts that the drug could not be standardized, that it had a 
number of undesirable side effects, and that its discontinuance often was fol-
lowed by rejection [5, 15]. Nevertheless, the role of ALG therapy probably 
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Table l. Immunosuppressive drug regimens and adjuncts for kidney transplantation and 
applied later for extrarenal organs 
Agents Year described Place Deficiencies Used 
and reported for 
livers 
Azathioprine 1962 [ 8] Boston ineffective, dangerous no 
Azathioprine-steroids 1963 [ 9] Denver suboptimal yes 
Thoracic duct drainage 1963 [21P Stockholm nuisance: requires yes 
as adjunct 20-30 days 
pretreatment 
ALG as adjunct 1966 [ 6] Denver suboptimal yes 
Cyclophosphamide 1970 [20] Denver no advantage except yes 
substitute for for patients with 
azathioprine azathioprine toxicity 
Total lymphoid 1979 [23, 24] Palo Alto, dangerous; extensive yes 
irradiation Minn. preparation; not 
quickly reversible 
Ciclosporin alone 1978-1979 [27] Cambridge suboptimal yes 
Ciclosporin-steroids 1980 [29] Denver under evaluation yes 
Monoclonal ALG 1981[17] Boston under evaluation yes 
as adjunct 
1 It was not realized until much later that pretreatment for 3 -4 weeks before transplantation 
was a necessary condition [22]. 
will become increasingly important since it is now possible to raise potent and 
highly standardized antilymphoid antibodies with the monoclonal antibody 
techniques of Kohler and Milstein [16]. The first trials were carried out by Co-
simi et al. [17] using monoclonal antibodies raised against mature T lympho-
cytes (T 3)' These studies and others which have followed have shown that other-
wise intractible rejections often can be reversed with good monoclonal 
preparations [18, 19]. However, if maintenance therapy is being provided with 
azathioprine and prednisone, there is a very high probability of recurrence 
of rejection when the course of monoclonal therapy is completed [17-19]. 
Other variations in immunosuppression between 1962 and 1979 are 
summarized in table I including the substitution of cyclophosphamide for 
azathioprine [20], and the use of thoracic duct drainage [21, 22] or totallym-
phoid irradiation [23,24] as an alternative to ALG for lymphoid depletion. 
None of these techniques has had a major impact on clinical transplantation. 
------_._------
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Fig. 1. Results obtained over a 16-yearperiod using the conventional immunosuppression 
shown in table I. Note the failure to improve the results despite the acquisition of considerable 
experience. 
With Liver Transplantation 
Most of our liver recipients from 1963 through 1979 had triple-drug 
immunosuppression with azathioprine, prednisone and ALG. In some, 
cyclophosphamide was substituted for azathioprine and in a few others, lym-
phoid depletion was achieved with thoracic duct drainage instead of ALG. 
Details of these variations are summarized elsewhere [25]. The failure of any 
of the variations to influence the survival after liver transplantation is evident 
from figure l. In the first trials from 1963 to 1976, only about one-third of the 
patients lived for as long as 1 year. In a smaller second series of 30 patients 
treated from 1976 to 1978, the I-year survival rose to 50% but this improve-
ment could not be sustained in the next 29 cases (fig. 1). 
The Ciclosporin Era 
In 1976, Borel et al. [26] reported studies in rodents ofa new immunosup-
pressive agent called cyclosporin A and in late 1979, Caine et al. [27] reported 
the first major clinical experience with this drug. 
With Renal Transplantation 
The supremely encouraging observation in Caine's experience was that 
ciclosporin allowed prolonged graft survival in almost half of his recipients 
of 32 kidneys, 2 livers, and 2 pancreases with no other immunosuppressive 
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drug [27]. This kind of systematic reliance upon a single agent to control rejec-
tion had never been feasible before. Although Caine's publication became 
one of the most important in the history of clinical transplantation, it con-
tained three pieces of information so troubling that further clinical trials were 
jeopardized. First was a high incidence oflymphomas. Second, none of the 
kidney recipients had normal graft function. Third, there had been a high 
patient mortality. The way in which these adverse findings have been 
explained or minimized in subsequent trials will be mentioned now. 
The Development of Lymphomas. Amongst Caine's first 32 kidney recipi-
ents, there were 3 who developed malignant lymphomas [27]. The possibility 
that ciclosporin had a unique capacity to produce lymphomas in humans 
thus vitiating its value had to be seriously considered. 
Fortunately, the lymphoma threat has become less and less ominous as 
information about the etiology and appropriate treatment ofthese lesions has 
emerged. Almost from the outset, it was obvious that the lymphomas were 
complications of primary or secondary infection with the Epstein-Barr virus 
[28, 29]. At first, it was speculated that lymphomas which produced a single 
immunoglobulin (monoclonality) already had become autonomous [28]. 
Ultimately, this doctrine was overthrown [30]. In a large number of patients 
followed by us, it was demonstrated that all of the ciclosporin lymphomas 
could be expected to disappear spontaneously ifimmunosuppressive therapy 
was stopped, and often if treatment was only lightened. This involution 
occurred whether the lesions were polyclonal or monoclonal. In recipients of 
kidneys, livers and hearts, reduction or discontinuance of immunosuppres-
sion was not necessarily followed by loss of the transplanted organ. The point 
was best made in our kidney recipients in whom therapy with ciclosporin and 
steroids usually was stopped [30]. 0f7 so treated, 4 retained their grafts which 
have continued to function for 1'/2 to 3'/2 years subsequently. After the tumors 
had disappeared, therapy at lower doses was reinstituted. 
An example of the manipulation of therapy in a liver recipient who 
developed a lymphoma of the tonsils and pharynx is shown in figure 2. Ciclo-
sporin therapy was cut to about half of the preceding dose and the prednisone 
doses were brought to even lower levels. The child received an emergency 
tracheostomy. Within a few days, the fever and other systemic manifestations 
of the lymphoma had gone, the gross lesions had melted away, and recovery 
was assured. No changes whatsoever were seen in the liver function at this 
time, supporting the conclusion that the patient had been over-
immunosuppressed. 
TEMPERATURE 
'C 
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Fig. 2. The treatment of lymphoma in a pediatric liver recipient by reduction of both 
ciclosporin and prednisone doses. The airway was protected with a tracheostomy. but within a 
few weeks after lightening immunosuppression, the cervical tumors disappeared. Bx= Biopsy. 
The development of de novo malignancies in immunosuppressed 
patients is not unique to ciclosporin. It has been a well-known complication 
of therapy with azathioprine and prednisone (with or without ALG) since the 
1960s [31, 32]. With conventional immunosuppression there has been an 
extremely high incidence of epithelial cancers, which have outnumbered the 
lymphomas by a ratio of about 4: I [33]. Under ciclosporin-steroid therapy. 
there has been little or no increase in the incidence of the epithelial tumors. 
Thus, the risk of the development of malignancies is probably considerably 
less with ciclosporin than with conventional immunosuppression, even if one 
considers the lymphomas to be true tumors, a concession that may not be 
valid [34]. 
0 
120 
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Ciclosporin Nephrotoxicity and Its Prevention. Of the kidney recipients 
first reported by Caine et al. [27J, none had normal renal function, a finding 
which CaIne attributed to universal ciclosporin nephrotoxicity. In retrospect, 
part of the problem was failure to distinguish rejection from drug toxicity 
[29J. Nevertheless, many subsequent reports including our own [29, 35, 36] 
have shown that nephrotoxicity is the most limiting side effect of ciclosporin. 
It was immediately obvious in our first trials with ciclosporin in late 1979 
that the full exploitation ofthe drug would not be possible without combining 
it with other agents, of which prednisone was the most important [29, 36]. 
By so doing, it was possible to minimize the contribution of homograft rejec-
tion to poor renal function, and at the same time to ameliorate the nephro-
toxicity by reducing the requisite doses of ciclosporin. Since then, other 
drugs have been proposed and! or tried in modifications of the 'pharmaco-
logic cocktail' concept [37, 38], but the ciclosporin-steroid combination re-
mains the benchmark. Normal renal transplant function has become the 
rule. 
It is not hard to envision ciclosporin-steroid therapy as the modern ana-
logue of the original double-drug therapy with azathioprine and steroids 
(table I). As a further analogy, the next logical step may be development of 
new 'triple-drug' programs analogous to azathioprine, prednisone and ALG 
(see table I) but with ciclosporin-steroids being the baseline therapy to which 
one of the monoclonal ALG preparations which are undergoing preliminary 
clinical trials may be added. Our present opinion is that monoclonal ALG 
should be used to 'rescue' patients in whom rejection cannot be controlled 
with ciclosporin-steroid therapy or in whom there are severe limitations for 
one reason or other to the amounts of ciclosporin that can be safely given. 
Such limitations are particularly important in applying knowledge about 
immunosuppression obtained from the kidney transplant model to the 
transplantation of other organs such as the heart and liver since secondary 
renal failure is common in patients with cardiac and hepatic disease thereby 
complicating the use of ciclosporin. 
We have used OKT3 monoclonal antibody therapy in a number of our 
kidney recipients. If rejection has developed despite ciclosporin-steroid ther-
apy, reversal with OKT3 antibody usually has been striking (fig. 3). With the 
first dose of the monoclonal ALG, the circulating T lymphocytes are practi-
cally eliminated (fig. 3). Recurrence of rejection after the monoclonal anti-
body course has been completed has been far less common using baseline 
therapy with ciclosporin-steroids than previously reported with azathio-
prine-prednisone maintenance [17-19J. 
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Fig. 3. Course of a patient who developed inexorable rejection in spite of good blood levels 
of ciclosporin and despite a second burst of high-dose steroid therapy. The rejection was imme-
diately reversed with OKT-3 therapy and with good function for the ensuing 8 months. Note 
the prompt reduction in circulating T lymphocytes. 
High Patient Mortality. The heavy mortality with the first use of ciclo-
sporin [27] apparently was a reflection of a learning experience in which cyto-
toxic drugs and steroids were combined with ciclosporin with lethal effects. 
Even in our first trials with the far safer ciclosporin-steroid combination, the 
I-year patient mortality was l3.6% [39], but in the following year, the I-year 
mortality was reduced to 2% [40]. Since then, most groups using ciclo-
sporin-steroid therapy have had a mortality of less than 5%. Ciclo-
sporin-steroid therapy has been the safest of the therapeutic regimens yet 
tried. 
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Fig. 4. Increasing numbers of liver transplantations at the University of Pittsburgh 
between 1981 and 1984. Note the significant number of retransplant at ions. 
With Liver Transplantation 
In 1980, cidosporin and prednisone were used to treat 12 patients under-
going liver replacement. Two other liver recipients died on the operating 
table for a total patient pool in that year of 14 of whom 11 (78%) lived out 
the first year. If one counted only those who actually survived the operation 
to be able to receive drug therapy, the success rate was 11 (91.7%) of 12. 
Case Numbers. These improved results became known in 1981 [41] and 
almost immediately a remarkable effect was seen on the case numbers. Incre-
ments occurred year-by-year until in the calendar year of 1984, a total of 166 
orthotopic liver transplantations were performed at the University of Pitts-
burgh (fig. 4). Augmented activity in other centers throughout the world has 
been documented elsewhere [42]. 
The Increasing Use of Pharmacologic Monitoring. In our early trials of 
cydosporine-steroid therapy in renal transplantation, primary cadaveric kid-
ney graft survival of 80-90% was achieved without knowing what the ciclo-
sporin blood levels were. The clinical judgement in managing such patients 
reflected a deliberate effort to balance the possibilities of rejection against 
those of nephrotoxicity [36] and to treat both. 
When techniques became available for assessment of whole blood or 
plasma ciclosporin concentration using radioimmunoassay (RIA) or high 
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Fig. 5. The use of cic\osporin and steroids. Note that the ciclosporin initially is given 
intravenously (i.v.) and that the i.v. therapy is continued long after the drug is begun orally. The 
switch from double-route ciclosporin therapy to the oral route alone is carefully monitored with 
ciclosporin blood levels. Note the seeming increase in enteral absorption after clamping of the 
T-tube. the insistence upon maintaining high blood levels of ciclosporin in spite of obvious low-
grade nephrotoxicity, and the intensification of steroid therapy with either a cycle or intermittent 
bolus administration with suspicion of rejection. Large arrows = I g Solu-Medrol; small arrows 
= I g Solu-Cortef. By permission of Starzl et al. [42]. 
performance liquid chromatography (HPLC). it became popular to rely 
heavily on the results of these tests for management decisions. Recipients of 
liver transplantation have benefited from this practice since intestinal 
absorption of ciclosporin after liver transplantation has been unpredictable. 
To assure adequate ciclosporin blood concentrations. it has frequently been 
necessary to administer the drug both intravenously and by mouth for several 
!: 
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Fig. 6. Marked improvement in results of liver transplantation after the introduction of 
ciclosporin-steroid therapy in early 1980. 
days, weeks or even months postoperatively (fig. 5). As absorption improves 
with the oral route, the intravenous doses are slowly reduced. However, blind 
faith in the ciclosporin blood levels cannot be used to replace good clinical 
judgement since toxicity of the drug including that affecting the liver as well 
as the kidney does not have an absolute correlation with the blood level. 
Survival after Ciclosporin. From 1963 through 1979, 170 patients were 
treated with conventional immunosuppression. The chances of living for a 
year after liver transplantation were only about 1 in 3 (fig. 6). Subsequently, 
244 liver recipients were provided with ciclosporin-steroid therapy between 
March 1980 and 1 July 1984, allowing follow-ups 10 months to more than 
5 years. The chances of I-year survival were more than doubled. Actuarial 
projections beyond I year indicate that these gains will be sustained for at 
least half a decade (fig. 6). 
In a later section, more detail will be given of the influence of age and 
underlying disease upon the outcome. In the meanwhile, other factors that 
could influence the results will be considered briefly. 
The Role of Tissue Typing 
In patients treated with ciclosporin-steroids after renal transplantation, 
the antigen matching at the A. B. or D loci has had little influence on the 
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results. Such matching has not even been attempted for liver recipients. It is 
unlikely that this kind oftissue matching will playa significant role in further 
developments in liver transplantation. 
A surprising finding has been the remarkable resistance of the liver to 
hyperacute rejection [43, 44]. There has been no obvious penalty with 
transplantation oflivers to recipients whose sera contain the cytotoxic anti-
graft antibodies that almost invariably lead to immediate loss of kidney 
grafts. Furthermore, many liver transplantations have been and are being 
carried out across the ABO blood group barriers which frequently (although 
not invariably) cause hyperacute rejection of kidneys as the consequence of 
antigraft isoagglutinins [l3]. These observations have simplified some of the 
logistic problems ofliver transplantation. 
Improvements in Technique 
The technical principles of liver transplantation have been well worked 
out for almost 2 decades but 2 highly significant developments have occurred 
in the last few years. These are perfection of pump-driven veno-venous 
bypasses and the standardization of biliary tract reconstruction. 
The Veno- Venous Bypass 
When liver transplantation was first carried out in dogs, an obligatory 
condition for success was decompression of the vena caval and portal venous 
systems that had to be occluded while the native liver was removed and the 
new organ was sewn in [1, 2]. In the first clinical trials, it was found possible 
to omit this step [5] and for a number of years bypasses were not used. With-
out bypasses, the urgency with which the transplantation was performed was 
comparable to that in the early days of heart surgery when open cardiac oper-
ations were performed under inflow occlusion. 
In the last 3 years, pump-driven veno-venous bypass techniques without 
heparin have been developed (fig. 7) which have removed this urgency and 
which have allowed the avoidance of the venous hypertension that otherwise 
is inevitable during the anhepatic phase [45-47]. The advantages of veno-
venous bypasses include: (1) improved intraoperative cardiovascular stabil-
ity; (2) preservation of renal function by avoidance of the renal-venous hy-
pertension; (3) diminished blood loss; (4) reduced trauma to the gastrointes-
tinal tract by avoidance of the portal venous hypertension, and (5) creation 
of an operating room ambience compatible with training a new generation 
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Fig. 7. Pump-driven bypass. By permission of Griffith et al. [46]. 
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of surgeons who in turn will set up numerous new centers in the United States 
and other countries. 
The veno-venous bypass has changed the technical strategy of liver 
transplantation in important ways. In the past, when time was such a critical 
factor during the anhepatic phase, it was impossible to obtain meticulous 
hemostasis in the bare areas opened up by removal of the diseased native 
liver. Even had there been time, it was often impossible to clean up and make 
dry the raw surfaces which were exuding blood at a voluminous rate because 
of venous hypertension. Control of bleeding by mechanical means was 
frequently impossible until the new liver was in place and until the obstructed 
venous beds were decompressed by opening the caval and portal venous 
anastomoses. 
If veno-venous bypass is used, the technique shown in figure 8 can be 
applied whereby most or all of the bare areas are closed by running sutures 
[48]. Although these maneuvers may require an hour or longer before the 
anastomoses are started, the investment pays rich dividends later in ease of 
hemostasis. 
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Fig. 8. Elimination of the raw areas in the hepatic fossa with continuous Prolene suturing. 
See text for details. By permission of Starzl et al. [48]. 
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Fig. 9. Completed orthotopic liver transplantation. A Biliary tract reconstruction with 
choledochocholedochostomy. B Biliary tract reconstruction with choledochojejunostomy, using 
a Roux limb. By permission of Starzl et al. [25]. 
Biliary Tract Reconstruction 
Until about 8 years ago, biliary tract reconstruction was called the 
Achilles heel of liver transplantation with failure rates that were as high as 
30-50% [49, 50]. At that time, the gallbladder was usually used for reconstruc-
tion, the pathway of bile excretion being from the common duct through the 
cystic duct and gallbladder and into the intestine. Duct to duct and duct to 
bowel reconstruction were not employed frequently. 
Today, all biliary tract reconstructions are performed by one or the other 
of the techniques shown in figure 9, namely choledochocholedochostomy 
with aT-tube stent, or choledochojejunostomy to a Roux limb of jejunum. 
With these procedures, 90% or more of the biliary tract anastomoses are suc-
cessful on the first occasion and even when there are complications, these 
usually are easily rectified. 
- ---------------------------~ 
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Fig. 10. In situ infusion technique used when the kidneys and liver are removed from the 
same donor. R.g.a. = Right gastric artery; G .d.a. = gastroduodenal artery; S.a. = splenic artery; 
S.v.= splenic vein; P.v. = portal vein; S.m.v.= superior mesenteric vein. By permission of Starzl 
et al. [51]. 
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Fig. 11. Method of rapid liver cooling that can be done without any preliminary dissection 
except for insertion of a distal aortic cannula and cross-clamping of the aorta at the diaphragm. 
The infusion fluid quickly gets into the portal system via the splanchnic capillary bed, providing 
double inflow cooling. By permission of Starzl et al. [42]. 
Organ Removal and Preservation 
Great advances have been made in multiple organ removal and a rela-
tively standard procedure is being used throughout most of the United States 
[51]. The operation is done through a complete midline incision from the 
suprasternal notch to the pubis. including splitting of the sternum. The prin-
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Table II. Indications for liver transplantation in 140 adults 
Indication 
Acute hepatic necrosis 
Budd-Chiari syndrome 
Cirrhosis 
Inborn errors of metabolism 
Alpha-I-antitrypsin deficiency 
Wilson's disease 
Tyrosinemia 
Primary biliary cirrhosis 
Primary hepatic tumors 
Secondary biliary cirrhosis 
Sclerosing cholangitis 
Other 
Number 
3 
5 
46 
11 
6 
3 
1 
36 
13 
5 
19 
2 
383 
Percent 
2.1 
3.6 
32.9 
7.9 
4.3 
2.1 
0.7 
25.7 
9.3 
3.6 
13.6 
1.4 
ciple followed is to dissect the aorta for cross-clamping at a level which will 
allow intraaortic infusion of cold fluids which will pass into the organs to be 
removed. If the liver is to be one of these organs, dissection of the liver hilum 
is carried out after which the liver can be infused through both the aorta and 
portal vein (fig. 10). The kidneys also are cooled by the aortic perfusion. In 
the example shown in figure 10, the liver and both kidneys are to be removed. 
With minor modifications, the heart can also be excised. 
This procurement technique requires 'brain death' conditions with 
stable cardiovascular function. An alternative with which we have had recent 
experience can be done swiftly, and in donors who have had cardiac arrest 
[42]. With this so-called fast method, a cross-clamp is placed on the aorta near 
the diaphragm and cold solutions (usually the high potassium, high magne-
sium concentration Collin's solution) are infused rapidly. Blood enters the 
liver through the normal celiac axis route but also through the portal vein af-
ter passing through the splanchnic capillary bed (fig. 11). The portal venous 
blood quickly becomes almost red cell free. 
The cold ischemia limit which is permissible for a human liver graft has 
been set arbitrarily at 10 h, but great efforts are made to work within a 5- or 
6-hour time frame. One of the most urgent needs in liver transplantation is 
the development of better methods of preservation. Any technique which 
would allow safe preservation of livers for the better part of a day would 
revolutionize the field over night. 
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Table III. Indications for liver transplantation in 104 children 
Indication 
Biliary atresia 
Budd-Chiari syndrome 
Cirrhosis 
Familial cholestasis 
Inborn errors of metabolism 
Alpha-I-antitrypsin deficiency 
Wilson's disease 
Tyrosinemia 
Neonatal hepatitis 
Secondary biliary cirrhosis 
Sclerosing cholangitis 
Other 
Indicationsfor Transplantation and Results 
384 
Number Percent 
56 53.8 
1 1.0 
10 9.6 
7 6.7 
23 22.1 
15 14.4 
4 3.8 
3 2.9 
3 2.9 
1.0 
1 1.0 
2 1.6 
The indications for liver replacement in the developmental phase of this 
field have been documented elsewhere [25] and will not be mentioned here. 
Since the beginning ofthe ciclosporin era, 244 patients underwent this proce-
dure between March 1980 and 1 July 1984. In tables II and III are shown the 
principal indications for these operations. In about 10% of cases, there were 
multiple pathologic diagnoses such as the incidental presence of primary 
hepatic malignancies in livers with a variety of underlying chronic diseases. 
The profile of diseases in pediatric patients (less than 18 years) has been 
different than that in adults. In adults, postnecrotic cirrhosis has been the 
most important reason for proceeding (table II). Other common diseases in 
adults have been primary biliary cirrhosis and sclerosing cholangitis (ta-
ble II). In children, more than half of all the transplantations have been done 
for biliary atresia, the only other large group being heterogenous collection 
of inborn errors of metabolism (table III). The inborn errors if they are 
hepatic-based are cured permanently by liver replacement since the pheno-
type of the new liver remains that of the original donor [25]. 
Influence of Age on Survival 
Aside from the fact that the disease profiles leading to transplantation 
are different in children versus adults, another justification for stratification 
Liver Transplantation in the Cic1osporin Era 385 
PERCENT SURVIVAL 
lOO%GJ----------------------------, Pediatric series 
80 
60 
40 
20 
12 18 24 30 36 
MONTHS 
42 48 54 60 
N = 86 
---->I<-
Adult series 
N = 84 
---e-
Fig. 12. Results with adult versus pediatric liver transplantation under conventional 
immunosuppression between 1963 and early 1980. 
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Fig. 13. Comparison of results in adult and pediatric recipients during the ciclosporin era 
of 1980-1984. 
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Fig. 14. Percentages of liver transplantations in pediatric versus adult recipients at the 
University of Pittsburgh from 1981 through most of 1984. 
into adult and pediatric categories is the influence of age on survival. It was 
noted in the days of conventional immunosuppression that the results were 
better in pediatric recipients (fig. 12). The disparity in results in pediatric ver-
sus adult cases has been even more striking during the ciclosporin era (fig. 13). 
The actuarial 5-year survival in adults is projected at about 50%, compared 
to more than 70% for the pediatric recipients (fig. 13). In view of the impor-
tance ofthe age factor, it will be important for groups reporting results to stip-
ulate age distribution in their series. In our own experience using conven-
tional immunosuppression from 1963 to 1979, half of the recipients were 
infants, children and teenagers. In the subsequent years using ciclosporin, the 
pediatric component has never been this high (fig. 14). 
With the appropriate age stratification, meaningful comparisons 
become possible between what was achievable in the pre-ciclosporin era ver-
sus now. In adults, the projected 5-year survival after liver transplantation, 
while still unsatisfactory, is nearly 3 times better than it was previously 
(fig. 15). In children, the divergence of results using conventional im-
munosuppression compared to the present time is even more striking (fig. 
16). 
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Fig_ 16. Survival of pediatric patients in the pre-cic1osporin versus the cic1osporin era_ 
Notice the remarkably high survival of children treated with cic1osporin-steroids during the first 
postoperative year as well as the fact that subsequent losses were extremely uncommon. 
Starzlll watsukil Shawl Gordon/Esquivel 
PERCENT SURVIVAL 
100%41--------------------, 
60 
40 
20 
12 18 24 30 36 42 48 
MONTHS 
388 
Primary biliary 
cirrhosis (N :; 36) 
"""+--
Sclerosing 
cholangitis (N :; 19) 
"'0 
Inborn errors of 
metabolism (N :::: 11) 
- -8-
Fig. 17. The lack of influence ofthe underlying disease in adults treated for primary biliary 
cirrhosis, sclerosing cholangitis. and inborn errors of metabolism. 
The Influence of Diseases Upon Prognosis 
There are no diseases for which transplantation has been carried out in 
the past which can be automatically precluded from future trials. Usually, the 
nature of the original disease has not profoundly influenced the outcome 
after transplantation. For example, the results in adults have been similar 
with such diverse diseases as primary biliary cirrhosis, sclerosing cholangitis, 
and inborn errors of metabolism (fig. I?). Nevertheless, there may be some 
high risk diseases. So far, the results with postnecrotic cirrhosis and with pri-
mary hepatic tumors have been inferior (fig. 18). With cirrhosis, the principal 
explanations have been the technical difficulties of the operation caused by 
the pathologic process, the generally poor condition of the cirrhotic patients, 
and almost universal recapitulation of their original chronic active hepatitis 
in B virus carriers. 
In patients whose reason for liver replacement was a primary hepatic 
malignancy which could not be removed by conventional subtotal hepatic 
resection, the early mortality has been quite low with more than 80% of the 
recipients being alive at 6 months. The steady decline thereafter (fig. 18) has 
been caused by recurrent tumor which can be expected in 80% or more of 
patients who live long enough for metastases to be detected. The only accept-
able results thus far have been in patients with the slow-growing and nonag-
gressive fibrolamellar hepatomas which recently have been recognized to be 
-------------------------
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Fig. 18. The life survival curves of patients with 2 'bad' diseases - cirrhosis and primary 
hepatic malignancy. Note the very high survival of patients with malignant disease during the 
first half year (85%), but with a steady decline thereafter which was due primarily to the develop-
ment of metastases. 
a favorable variant within the larger hepatoma category [52]. It has been 
exceptionally disappointing to note that no patient in the world has ever been 
cured of a duct cell carcinoma by liver transplantation. This has been unex-
pected since the small duct cell carcinomas at the confluence of the right and 
left hepatic ducts (Klatskin tumors) were once thought to be an almost ideal 
indication for liver replacement. 
In children, the results have been about the same in all of the main dis-
ease categories (fig. 19). It was thought once that the technical problems in 
frequently reoperated children with biliary atresia would result in an 
increased mortality. Almost all such infants and children have had portoen-
terostomies and many have had multiple later surgical interventions in and 
around the hepatic hilum. Although transplantation is technically much 
more difficult under such circumstances, there has been no demonstrable 
penalty in terms either of early or late survival (fig. 19). 
The Role of Retransplantation 
Before the ciclosporin era, retransplantation in the event offailure of the 
first liver was almost never successful. Twenty-one patients had retransplan-
tations carried out between 1963 and 1979 under conventional immunosup-
----------------~-------------------
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Fig. 19. The lack of influence of underlying disease on the survival of children undergoing 
liver transplantation. 
pression with only 4 patients living for as long as an additional half year. Even 
these 4 exceptional recipients died 6, 12, 13 and 16 months after retransplan-
tation. 
The effectiveness of retransplantation has improved greatly since the 
introduction of ciclosporin, with a subsequent I-year survival of almost 50% 
[53]. The success rate for patients whose grafts have been in place for some 
time and failed slowly because of rejection has been high. The worst results 
have been in patients with immediate and serious technical complications 
and those whose grafts have undergone a rapid and uncontrolled rejection 
in the first week or two. 
The role of retransplantation in the future has been somewhat clouded 
by the enormous economic ramifications of early technical or other com plica-
tions serious enough to warrant replacement of the graft. At The University 
of Pittsburgh hospitals, the costs of liver replacement averaged less than 
$ 100,000 if only one transplantation was performed. In contrast, the bills for 
patients receiving multiple grafts (usually 2 but as many as 3) have been as-
tronomical and have averaged almost 3 times as much as for patients treated 
successfully from the beginning. 
Both in adults and in children. but particularly the latter, technical 
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complications have played an important role in necessitating attempts at 
retransplantation [53]. The lesson has been clear that if a perfect operation 
is not performed the first time for any reason, the cost will be prodigious and 
will have to be borne by the patient or more commonly the health insurance 
carrier. In future years, it will become important to try to identify those 
patients for whom retransplantation offers little or no chance of survival so 
that expensive and ineffective attempts can be avoided with some degree of 
accuracy. 
Summary 
During the last 5 years, liver transplantation has become a service as opposed to an 
experimental operation. The most important factor in making this possible has been the intro-
duction of ciclosporin-steroid therapy. At the same time, liver transplantation has been made 
more practical by improvements in surgical technique, including perfection of intraoperative 
veno-venous bypasses and the standardization of biliary tract reconstruction. Tissue typing and 
matching has played no role in improving the results of liver transplantation. With the demon-
stration that preformed antibody states are irrelevant, even avoidance of positive cross-matches 
caused by cytotoxic antibodies and observance of ABO blood group barriers have become 
unnecessary if the recipient's needs are great. With the exceptions of malignancy and cirrhosis, 
the nature of the underlying hepatic disease has not profoundly influenced the results. 
Retransplantation has played an important role in improving survival, although the costs of 
retransplantation have been extremely high. Many aspects of liver transplantation need to be 
improved including the development of better methods of preservation which will allow the reci-
pient operations to be done in a more leisurely manner and at more convenient times. 
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